|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CACUL1 |
Gene summary for CACUL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CACUL1 | Gene ID | 143384 |
| Gene name | CDK2 associated cullin domain 1 | |
| Gene Alias | C10orf46 | |
| Cytomap | 10q26.11 | |
| Gene Type | protein-coding | GO ID | GO:0000082 | UniProtAcc | Q86Y37 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 143384 | CACUL1 | LZE4T | Human | Esophagus | ESCC | 2.71e-12 | 3.89e-01 | 0.0811 |
| 143384 | CACUL1 | LZE7T | Human | Esophagus | ESCC | 1.36e-04 | 3.72e-01 | 0.0667 |
| 143384 | CACUL1 | LZE8T | Human | Esophagus | ESCC | 7.14e-03 | 1.27e-01 | 0.067 |
| 143384 | CACUL1 | LZE20T | Human | Esophagus | ESCC | 2.95e-05 | 1.63e-01 | 0.0662 |
| 143384 | CACUL1 | LZE24T | Human | Esophagus | ESCC | 1.90e-23 | 7.57e-01 | 0.0596 |
| 143384 | CACUL1 | LZE6T | Human | Esophagus | ESCC | 4.69e-02 | 1.91e-01 | 0.0845 |
| 143384 | CACUL1 | P1T-E | Human | Esophagus | ESCC | 2.28e-03 | 3.76e-01 | 0.0875 |
| 143384 | CACUL1 | P2T-E | Human | Esophagus | ESCC | 3.99e-48 | 8.73e-01 | 0.1177 |
| 143384 | CACUL1 | P4T-E | Human | Esophagus | ESCC | 2.92e-24 | 6.58e-01 | 0.1323 |
| 143384 | CACUL1 | P5T-E | Human | Esophagus | ESCC | 3.00e-26 | 6.72e-01 | 0.1327 |
| 143384 | CACUL1 | P8T-E | Human | Esophagus | ESCC | 4.20e-25 | 4.87e-01 | 0.0889 |
| 143384 | CACUL1 | P9T-E | Human | Esophagus | ESCC | 6.97e-07 | 2.24e-01 | 0.1131 |
| 143384 | CACUL1 | P10T-E | Human | Esophagus | ESCC | 1.01e-23 | 1.02e-01 | 0.116 |
| 143384 | CACUL1 | P11T-E | Human | Esophagus | ESCC | 2.64e-25 | 1.09e+00 | 0.1426 |
| 143384 | CACUL1 | P12T-E | Human | Esophagus | ESCC | 3.52e-29 | 5.64e-01 | 0.1122 |
| 143384 | CACUL1 | P15T-E | Human | Esophagus | ESCC | 6.28e-21 | 5.01e-01 | 0.1149 |
| 143384 | CACUL1 | P16T-E | Human | Esophagus | ESCC | 7.40e-37 | 7.43e-01 | 0.1153 |
| 143384 | CACUL1 | P17T-E | Human | Esophagus | ESCC | 1.21e-07 | 3.34e-01 | 0.1278 |
| 143384 | CACUL1 | P19T-E | Human | Esophagus | ESCC | 4.44e-05 | 6.42e-01 | 0.1662 |
| 143384 | CACUL1 | P20T-E | Human | Esophagus | ESCC | 2.73e-18 | 4.22e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
| GO:000008214 | Esophagus | ESCC | G1/S transition of mitotic cell cycle | 134/8552 | 214/18723 | 4.04e-07 | 5.55e-06 | 134 |
| GO:004484314 | Esophagus | ESCC | cell cycle G1/S phase transition | 148/8552 | 241/18723 | 5.68e-07 | 7.48e-06 | 148 |
| GO:004586018 | Esophagus | ESCC | positive regulation of protein kinase activity | 219/8552 | 386/18723 | 6.91e-06 | 6.97e-05 | 219 |
| GO:003367420 | Esophagus | ESCC | positive regulation of kinase activity | 260/8552 | 467/18723 | 7.26e-06 | 7.22e-05 | 260 |
| GO:00458606 | Liver | NAFLD | positive regulation of protein kinase activity | 65/1882 | 386/18723 | 2.22e-05 | 6.13e-04 | 65 |
| GO:00336747 | Liver | NAFLD | positive regulation of kinase activity | 74/1882 | 467/18723 | 5.16e-05 | 1.19e-03 | 74 |
| GO:0044772 | Liver | NAFLD | mitotic cell cycle phase transition | 67/1882 | 424/18723 | 1.25e-04 | 2.39e-03 | 67 |
| GO:0044843 | Liver | NAFLD | cell cycle G1/S phase transition | 43/1882 | 241/18723 | 1.40e-04 | 2.63e-03 | 43 |
| GO:0000082 | Liver | NAFLD | G1/S transition of mitotic cell cycle | 39/1882 | 214/18723 | 1.78e-04 | 3.14e-03 | 39 |
| GO:00447721 | Liver | Cirrhotic | mitotic cell cycle phase transition | 139/4634 | 424/18723 | 1.02e-04 | 1.06e-03 | 139 |
| GO:00000821 | Liver | Cirrhotic | G1/S transition of mitotic cell cycle | 72/4634 | 214/18723 | 2.07e-03 | 1.28e-02 | 72 |
| GO:00448431 | Liver | Cirrhotic | cell cycle G1/S phase transition | 77/4634 | 241/18723 | 6.68e-03 | 3.30e-02 | 77 |
| GO:004586011 | Liver | Cirrhotic | positive regulation of protein kinase activity | 117/4634 | 386/18723 | 7.07e-03 | 3.41e-02 | 117 |
| GO:00447722 | Liver | HCC | mitotic cell cycle phase transition | 240/7958 | 424/18723 | 2.47e-09 | 6.84e-08 | 240 |
| GO:00448432 | Liver | HCC | cell cycle G1/S phase transition | 134/7958 | 241/18723 | 2.60e-05 | 2.70e-04 | 134 |
| GO:00000822 | Liver | HCC | G1/S transition of mitotic cell cycle | 119/7958 | 214/18723 | 7.11e-05 | 6.39e-04 | 119 |
| GO:004586021 | Liver | HCC | positive regulation of protein kinase activity | 194/7958 | 386/18723 | 1.16e-03 | 6.54e-03 | 194 |
| GO:003367411 | Liver | HCC | positive regulation of kinase activity | 230/7958 | 467/18723 | 1.72e-03 | 8.95e-03 | 230 |
| GO:00447728 | Oral cavity | OSCC | mitotic cell cycle phase transition | 255/7305 | 424/18723 | 5.29e-19 | 6.98e-17 | 255 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CACUL1 | SNV | Missense_Mutation | c.982N>A | p.Asp328Asn | p.D328N | Q86Y37 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-A2-A0EV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CACUL1 | SNV | Missense_Mutation | novel | c.1093T>C | p.Ser365Pro | p.S365P | Q86Y37 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.979) | TCGA-PL-A8LV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CACUL1 | insertion | In_Frame_Ins | novel | c.601_602insTTTTTGCTTACAATTTTGGAATTT | p.Ser201delinsIlePheAlaTyrAsnPheGlyIleCys | p.S201delinsIFAYNFGIC | Q86Y37 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| CACUL1 | SNV | Missense_Mutation | novel | c.1021A>G | p.Thr341Ala | p.T341A | Q86Y37 | protein_coding | tolerated(1) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CACUL1 | SNV | Missense_Mutation | c.313C>T | p.Pro105Ser | p.P105S | Q86Y37 | protein_coding | tolerated_low_confidence(0.12) | benign(0.043) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| CACUL1 | SNV | Missense_Mutation | novel | c.703N>C | p.Tyr235His | p.Y235H | Q86Y37 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CACUL1 | SNV | Missense_Mutation | c.29N>A | p.Gly10Glu | p.G10E | Q86Y37 | protein_coding | tolerated_low_confidence(0.23) | benign(0.014) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CACUL1 | SNV | Missense_Mutation | c.989N>C | p.Lys330Thr | p.K330T | Q86Y37 | protein_coding | deleterious(0) | possibly_damaging(0.906) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CACUL1 | SNV | Missense_Mutation | c.716N>T | p.Lys239Met | p.K239M | Q86Y37 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D5-6924-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CACUL1 | SNV | Missense_Mutation | novel | c.349N>C | p.Thr117Pro | p.T117P | Q86Y37 | protein_coding | tolerated(0.33) | benign(0) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |